DSM Biologics, a business unit of DSM Pharmaceutical Products, has announced that it has successfully enhanced the efficiency of its proprietary, yield-boosting XD technology from 2L to 50L using a CHO cell line, to support the latest research in biomanufacturing.

Rolf Douwenga, vice president, Global Technology was quoted as saying, “We are excited about the robustness of the scale-up to 50L scale, The data proves again that the XD technology is very consistent in scalability independent of the cell lines or types of recombinant proteins we have tested.”

By dramatically increasing the cell density and optimizing the conditions for protein production of a culture, DSM’s proprietary XD Technology offers a simple, elegant solution to substantially increase titers without changing the cell line or process media. The scale up runs at DSM demonstrated record viable cell densities up to 170 million cells/ml. Record titer improvements of five to 10 fold over standard fed-batch and perfusion processes have been consistently achieved in multiple mammalian cell systems including CHO and PER.C6. The technology has broad applicability and benefits to mammalian cell systems and across various target production molecules including monoclonal antibodies and recombinant proteins.

This improved performance has been achieved using off-the-shelf, chemically-defined media within a two week culture. Progress is underway for scale-up to the next level with results anticipated later in 2010. Jeremy Caudill, vice president, Sales and Business Development stated, “The results from DSM’s proprietary XD technology demonstrate a paradigm shift in biologics drug manufacturing. Companies can now substantially shrink their bioreactor size requirements by 5-10 fold, reducing the CAPEX required for building a new plant and ultimately reducing overall cost of goods.”

DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global provider of manufacturing technology and services to the biopharmaceutical industry.

Crucell's PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies.

DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries.